COMP <GO>
LXRX vs LLY // RSI-14 & 200D SMA MOMENTUM
Lexicon Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: LXRX 2
— LLY 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $1.48 (-0.34%) • MKT CAP: $658.5M
rsi-technicals
29.1
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
rsi-technicals
66.6
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LXRX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LXRX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.64% | +12.36 | LXRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.50% | 32.36% | -63.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.30% | 2.30% | -12.60 | LLY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 40.21% | -100.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 31.90% | -91.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 45.51% | +134.49 | LXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 29.1 | 66.6 | -37.55 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $658.5M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LXRX REV | LLY REV | LXRX GROSS % | LLY GROSS % | LXRX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $49.8M | $65.18B | 98.0% | 83.0% | -$67.9M | $16.81B |
| FY 2024 | $6.0M | $45.04B | 89.7% | 81.3% | -$179.8M | $8.82B |
| FY 2023 | $1.1M | $34.12B | — | 79.3% | -$161.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LXRX // BETA —
LLY // BETA 0.51